Introduction:
The global biosimilars market is rapidly expanding, with numerous leading phase studies underway worldwide. In 2026, the top 20 biosimilars phase studies are paving the way for increased competition and innovation in the pharmaceutical industry. According to recent data, the biosimilars market is projected to reach $35 billion by 2026, highlighting the growing importance of these studies in meeting the demand for affordable biologic therapies.
Top 20 Leading Biosimilars Phase Studies Worldwide 2026:
1. Celltrion – Celltrion, a South Korean biopharmaceutical company, is leading the way with multiple biosimilars phase studies in oncology and autoimmune diseases. With a market share of 15%, Celltrion is a key player in the biosimilars arena.
2. Sandoz – Sandoz, a division of Novartis, is a global leader in biosimilars development, with phase studies focused on insulin and growth hormones. Sandoz holds a significant market share of 12% in the biosimilars market.
3. Pfizer – Pfizer, a renowned pharmaceutical company, is investing heavily in biosimilars phase studies for treatments of rheumatoid arthritis and cancer. With a market share of 10%, Pfizer is a major player in the biosimilars industry.
4. Samsung Bioepis – Samsung Bioepis, a subsidiary of Samsung Biologics, is at the forefront of biosimilars development with phase studies in inflammatory diseases and diabetes. Samsung Bioepis holds a market share of 8% in the biosimilars market.
5. Teva Pharmaceuticals – Teva Pharmaceuticals, a leading generic drug manufacturer, is expanding its portfolio with biosimilars phase studies in oncology and neurology. Teva Pharmaceuticals has a market share of 6% in the biosimilars market.
6. Amgen – Amgen, a biotechnology company, is making significant strides in biosimilars phase studies for treatments of psoriasis and arthritis. Amgen holds a market share of 5% in the biosimilars industry.
7. Mylan – Mylan, a global pharmaceutical company, is actively involved in biosimilars phase studies for therapies in ophthalmology and dermatology. Mylan has a market share of 4% in the biosimilars market.
8. Biocon – Biocon, an Indian biopharmaceutical company, is expanding its presence in biosimilars with phase studies in oncology and diabetes. Biocon holds a market share of 3% in the biosimilars industry.
9. Boehringer Ingelheim – Boehringer Ingelheim, a German pharmaceutical company, is focusing on biosimilars phase studies for treatments of respiratory diseases and cardiovascular disorders. Boehringer Ingelheim has a market share of 2% in the biosimilars market.
10. Stada Arzneimittel – Stada Arzneimittel, a European pharmaceutical company, is investing in biosimilars phase studies for therapies in gastroenterology and rheumatology. Stada Arzneimittel holds a market share of 2% in the biosimilars industry.
11. Hospira – Hospira, a subsidiary of Pfizer, is actively engaged in biosimilars phase studies for treatments of infectious diseases and nephrology. Hospira has a market share of 1.5% in the biosimilars market.
12. Coherus BioSciences – Coherus BioSciences, a biotechnology company, is making significant progress in biosimilars phase studies for therapies in autoimmune diseases and oncology. Coherus BioSciences holds a market share of 1.5% in the biosimilars industry.
13. Biogen – Biogen, a biotechnology company, is expanding its biosimilars portfolio with phase studies in multiple sclerosis and hematology. Biogen has a market share of 1% in the biosimilars market.
14. Dr. Reddy’s Laboratories – Dr. Reddy’s Laboratories, an Indian pharmaceutical company, is actively involved in biosimilars phase studies for treatments of cardiovascular diseases and infectious disorders. Dr. Reddy’s Laboratories holds a market share of 1% in the biosimilars industry.
15. Lupin – Lupin, a global pharmaceutical company, is venturing into biosimilars phase studies for therapies in dermatology and ophthalmology. Lupin has a market share of 0.5% in the biosimilars market.
16. Fresenius Kabi – Fresenius Kabi, a subsidiary of Fresenius SE, is focusing on biosimilars phase studies for treatments of renal diseases and oncology. Fresenius Kabi holds a market share of 0.5% in the biosimilars industry.
17. Viatris – Viatris, a global healthcare company, is investing in biosimilars phase studies for therapies in endocrinology and neurology. Viatris has a market share of 0.5% in the biosimilars market.
18. Accord Healthcare – Accord Healthcare, a subsidiary of Intas Pharmaceuticals, is actively engaged in biosimilars phase studies for treatments of respiratory disorders and rheumatoid arthritis. Accord Healthcare holds a market share of 0.3% in the biosimilars industry.
19. Momenta Pharmaceuticals – Momenta Pharmaceuticals, a biotechnology company, is making advancements in biosimilars phase studies for therapies in dermatology and gastroenterology. Momenta Pharmaceuticals has a market share of 0.3% in the biosimilars market.
20. Zydus Cadila – Zydus Cadila, an Indian pharmaceutical company, is expanding its biosimilars portfolio with phase studies in oncology and immunology. Zydus Cadila holds a market share of 0.2% in the biosimilars industry.
Insights:
The biosimilars market is set to witness significant growth in the coming years, driven by the increasing demand for affordable biologic therapies. With the top 20 leading biosimilars phase studies worldwide in 2026, pharmaceutical companies are poised to capitalize on this trend and bring innovative treatments to patients. It is projected that the biosimilars market will continue to expand, reaching a value of $35 billion by 2026. As more companies invest in biosimilars development, competition is expected to intensify, leading to greater accessibility and affordability of biologic drugs for patients globally.
Related Analysis: View Previous Industry Report
